Key result
The ANP family of peptides demonstrates antiproliferative effects against various cancer cells in vitro and in vivo, leading to the recent entry of ANP-related agents into clinical trials for cancer.
Why the study?
Despite decades of research demonstrating antiproliferative effects of ANP family peptides on cancer cells, no anticancer drugs had been developed from ANP until recent events propelled two related agents into clinical trials.
Answers are grounded in this paper and cite their sources.
ANP family peptides, originally identified for their cardiovascular effects, demonstrate significant antiproliferative properties and are now entering clinical trials for cancer therapy.
Atrial natriuretic peptide (ANP) was discovered over 40 years ago, and the other members of the ANP family of peptides nearly 30 years ago. One of the effects of these peptides was found to be inhibition of the proliferation of both normal and cancer cells in vitro as well as in vivo. For the past 20 years, numerous studies have characterized the antiproliferative effects of ANP family peptides on cancer cells and proposed a role for them in the treatment of cancer. Yet, as of 2021, no anti-cancer drugs have been developed from ANP. Recently, however, events have propelled two ANPrelated agents into clinical development for treating cancer. The present mini review outlines the history of ANP, from its discovery to the recent entry of ANP-related peptides into clinical trials for cancer.
No takes yet. Share an insight, caveat, or question.
Michael R. Kozlowski (2021) conducted a review in Cancer. ANP family of peptides was evaluated. The ANP family of peptides demonstrates antiproliferative effects against various cancer cells in vitro and in vivo, leading to the recent entry of ANP-related agents into clinical trials for cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: